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Abstract
Background: The current chemotherapy for cutaneous leishmaniosis (CL) has a series of drug limitations such as toxic
side effects, long duration, high costs and drug resistance, which requires the development of new drugs or effective
alternatives to the CL treatment. Essential oils (EOs) are complex mixtures of secondary metabolites from various plants.
It has been shown that several EOs, or their constituents, have inhibitory activity against protozoa. Thus, this study aims
to evaluate the biological activity of different essential oils (EOs) on Leishmania (L.) amazonensis promastigotes forms,
as well as their cytotoxicity on mammalian cells and chemical composition.
Methods: Sixteen EOs were evaluated by mean of IC50/24 h and cytotoxicity against L6 cells (CC50/24 h) using
Resazurin assay. Only those EOs that presented better results for IC50/24 h were submitted to GC–MS analysis to
determine their chemical constitution.
Results: The EO from Cinnamodendron dinisii, Matricaria chamomilla, Myroxylon peruiferum, Salvia sclarea, Bulnesia
sarmientoi, Ferula galbaniflua, Siparuna guianensis and Melissa officinalis were the most active against L. amazonensis
with IC50/24 h ranging from 54.05 to 162.25 μg/mL. Analysis of EOs by GC–MS showed mainly the presence of
β-farnesene (52.73 %) and bisabolol oxide (12.09 %) for M. chamomilla; α-copaene (13.41 %), safrole (8.35 %)
and δ-cadinene (7.08 %) for M. peruiferum; linalool (28.80 %) and linalyl acetate (60.08 %) for S. sclarea;
guaiol (48.29 %) and 2-undecanone (19.49 %) for B. sarmientoi; ethyl phthalate (13.09 %) and methyl-8-pimaren-18-oate
(41.82 %) for F. galbaniflua; and neral (37.18 %) and citral (5.02 %) for M. officinalis.
Conclusion: The EO from F. galbaniflua showed to be effective against L. amazonensis promastigotes forms and
presented low cytotoxic activity against L6 cells. Thus, it represents a strong candidate for future studies aiming its
molecular activity on these pathogenic parasites.
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Background
Leishmaniasis, the third most important vector-borne
diseases, is caused by a protozoan parasite of the genus
Leishmania, which is transmitted to human by the bite
of sand flies. Leishmaniasis represents a complex disease
with diverse clinical manifestations and poses a public
health problem since it is a neglected tropical disease
with current high worldwide incidence [1, 2]. Globally,
more than 12 million individuals are infected, with
another 350 million at risk of infection, and nearly 2
million new cases are reported annually worldwide [3].
The disease is prevalent in 16 developed and 72 develop-
ing countries; nevertheless 90 % of cases are reported in
three regions: Sudan/Ethiopia/Kenya, India/Bangladesh/
Nepal and Brazil with as many as 0.02 to 0.04 million
deaths every year [3, 4].
Leishmaniasis can be divided into three forms, varying
in severity from self-healing cutaneous lesions, dermato-
logical ulcers in cutaneous leishmaniasis (CL), destructive
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form of mucocutaneous leishmaniasis, to deadly form of
visceral leishmaniasis (VL) [5]. CL is characterized by
ulcers on the skin that are often formed at the site of the
insect vector bite. Those ulcers can undergo metastasis of
the nasopharyngeal mucosa developing to tissue destruc-
tion, depending on the species of Leishmania involved [6].
Leishmania (Viannia) braziliensis and Leishmania (V.)
panamensis are responsible for cases of mucocutaneous
leishmaniasis in the Americas, although L. (V.) guyanensis
and L. (L.) amazonensis have been identified, especially, in
immuno-compromised hosts [6].
The first-line drugs for systemic treatment of leish-
maniasis are parenterally administered antimonials such
as the sodium stibogluconate (Pentostam®) and the N-
methyl glucamine antimoniate (Glucantime®) [7, 8] gen-
erally required for the treatment of CL in the New
World due to the risk of mucosal involvement [9]. This
current chemotherapy presents several issues such as
high cost, difficult administration and elevated toxicity,
associated with serious side effects [10], for instance
musculoskeletal pain, gastrointestinal disturbances, mild
to moderate headache, electrocardiographic QTs interval
prolongation and mild to moderate increase of liver and
pancreatic enzymes [11]. Second-line drug Pentamidine
and amphotericin B are not widely used due to their
high toxicity and cost. Miltefosine, the first oral anti-
leishmanial drug, is the treatment of choice for diffuse
cutaneous leishmaniasis and New World cutaneous
leishmaniasis caused by Leishmania braziliensis but in-
creasing resistance to this drug has been notified [12].
All antileishmanial drugs except miltefosine have to be
administrated parenterally. Most of these drugs are
toxic, requires prolonged hospitalization and close moni-
toring, which makes the treatment costly and beyond
the reach of most patients. Consequently, the develop-
ment of alternative therapies is a priority for the treat-
ment of leishmaniasis. As a strategy, the investigation of
extracts and compounds, with biological activity, isolated
from plants and used in traditional medicine is a prom-
ising in the research field for compounds with potential
action for the prophylaxis and chemotherapy of CL [13].
Essential oils (EOs) are complex mixtures of secondary
metabolites isolated from plants. In these mixtures, there
are 10–60 constituents at different concentrations, but
usually only 2–3 major constituents determine the
biological properties of the EO [14]. Those compounds
and their constituents present a broad pharmacological
spectrum, and they are used as analgesics, sedatives, anti-
inflammatory, and anti-spasmodic drugs, as well as anti-
microbials, antiprotozoals and antihelmintics [13, 15, 16].
It has been shown that several EOs or their constituents
have inhibitory activity on protozoa, especially Leishmania
[17–19]. For instance, Santos and colleagues demon-
strated that copaiba oil from Copaifera martii is a safer,
shorter, less-expansive, and more easily administered
antileishmanial drug [18]. Therefore, the purpose of
this present work was to analyze the effect of sixteen
EOs biological potential on L. amazonensis promasti-
gotes forms and L6 cells and chemical constitution,




EOs of Litsea cubeba fruits; Lavandula officinalis,
Matricaria chamomilla and Cananga odorata flowers;
Elettaria cardamomum seeds; Cinnamomum camphora,
Myroxylon peruiferum and Bulnesia sarmientoi barks;
Ferula galbaniflua resin; Salvia sclarea, Foeniculum offi-
cinalis, Cordia verbenaceae, and Melissa officinalis
leaves; Pelargonium graveolens leaves and stems were
purchased from QUINARI Cosmetic and Fragrances Inc.
(Maringá-PR, Brazil) with lot number 0717/05209/F.
EOs of Cinnamodendron dinisii and Siparuna guianensis
leaves were obtained as described by Andrade et al. [20].
Firstly, EOs and Amphotericin B 250 μg/mL (Sigma-
Aldrich, St. Louis, USA) were diluted in dimethylsulfox-
ide (DMSO) at 100 mg/mL and 50 μg/mL, respectively.
For use, the stock was diluted 5:100 in either Schneider
(Sigma-Aldrich) or RPMI-1640 (Sigma-Aldrich) media
(sub stock). DMSO final concentration in the experi-
ments never exceeded 0.5 %, a concentration that is not
harmful to parasites and L6 cells [13]. Stocks were
stored at 4 °C in the dark, to avoid degradation [21]. The
sub stock was freshly prepared before use.
Chemical composition of EOs
Gas chromatography–mass spectrometry (GC–MS) ana-
lysis was performed using a Shimadzu GC-2010 gas chro-
matograph coupled with GCMS-QP2010 Plus equipped
with auto sampler (model AOC-20i, Shimadzu, Columbia,
MD, USA) and GC–MS Solution software. Investigation
was performed with a Rtx-5MS capillary column (30 mm×
0.25 mm× 0.25 μm) at programmed temperature ranging
from 60 to 250 °C at 3 °C/min. Analysis conditions were:
injector temperature 250 °C, ion source interface
temperature 300 °C, analysis of masses between 40–
350 m/z, electron impact at 70 eV, column head pres-
sure at constant pressure of 59 kPa, column flow
1.02 mL/min, gas linear velocity: 36.8 cm/s, carrier gas:
helium, injected volume 1 μL (1:1000 in hexane) in
splitless. Constituents of EOs were identified by
comparing their mass spectral pattern and retention
indexes (RI) relative to a standard n-alkane series
(C9–C24) with those known in the literature and the
Wiley W9N08 database [13, 22].
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Parasites and culture conditions
The promastigotes forms of L. amazonensis (strain
MHOM/BR/77/LTB0016) were maintained at 28 °C in
Schneider medium supplemented with 10 % fetal bovine
serum (FBS) and 100 μg/mL gentamicin, with weekly
passages. For the screening of EOs biological potential,
promastigotes were collected from cultures at the mid-
log phase of growth (3-day-old culture). The parasite
strain was obtained from Fiocruz-COLPROT (Coleção
de Protozoários da Fiocruz).
Antileishmanial activity of essential oils in vitro
EOs serial dilutions, from 500 to 31.25 μg/mL, were pre-
pared on a 96-well cell culture plate. Afterwards, 1.35 ×
106 parasite/mL culture resuspended in 150 μL were
added to the plates and incubated for 24 h at 28 °C.
After this period, 20 μL of Resazurin solution were added
to a 2 mM final concentration in all wells [23, 24]. The
plates were incubated for further 4 h at 37 °C followed by
the fluorescence measurement under 570 nmex/595 nmem
in the microplate reader SpectraMax M5 (Molecular
Devices, Sunnyvale, CA, USA).
In vitro experiment was performed in triplicate and re-
peated twice independently. DMSO was used as control
in the same final concentration found in each dilution.
Amphotericin B was used as positive control at final
concentration ranging from 312.5 to 19.56 ng/mL.
The percentage of viable promastigotes cells was
determined by the equation [25]:
%P ¼ ð100 FaÞ=Fc
Where %P: percentage of viable promastigotes cells; Fc:
control fluorescence units; Fa: fluorescence units emitted
by the analyzed samples (with inhibitor).
Cytotoxic activity of essential oils in vitro
Uninfected L6 cell monolayers were washed with Phos-
phate Buffered Saline (PBS) for 5 min at 37 °C, washed
with RPMI medium pH 7.4 + 2.5 % FBS, centrifuged at
200 g for 10 min at 4 °C, resuspended in the same
medium and, finally, seeded into 96-well plates (5 × 104
cells/well). Plates were incubated at 37 °C for 24 h, then
the medium was removed and cells were washed with
PBS. Diluted EOs were added to overnight-adhered L6
cells and incubated for more 24 h at 37 °C. Cell viability
was assessed by 2 mM Resazurin as described above.
The percentage of viable cells was determined by the
equation [25]:
%V ¼ ð100 FaÞ=Fc
Where %V is the percentage of viable cells, Fc: control
fluorescence units; Fa: fluorescence units emitted by the
analyzed samples (with inhibitor). The selectivity index
(SI) was calculated by dividing CC50 for the IC50.
Statistical analysis
For both in vitro EOs biological potential, a randomized
complete block design (RBD) test was used, with 5 con-
centrations, 3 repetitions and 2 experiments (blocks) for
each sample. The statistical program used was SISVAR
[26]. Data were submitted to analysis of variance and the
averages compared by Scott-Knott test and regression,
both 5 % probability. The adjusted equations were used
to calculate the concentration needed to cripple 50 % of
L6 cells (CC50) or 50 % of the parasites (IC50).
Results
Antileishmanial and cytotoxic activity of essential oils in
vitro
Growth inhibitory activity by the selected EOs was
performed on L. amazonensis promastigotes forms at
concentrations ranging from 30 to 500 μg/mL. In the
test, the EOs of L. cubeba, E. cardamomum, L. officina-
lis, C. camphora and C. odorata did not show activity at
500 μg/mL (Table 1). Lower concentrations of the
remaining EOs were then evaluated to estimate the
IC50/24 h (Table 1). The most effective EO was of the
one from S. guianensis (48.55 ± 3.64 μg/mL), followed by
C. dinisii (54.05 ± 4.88 μg/mL), M. chamomilla (60.16 ±
4.24 μg/mL), C. verbenaceae (64.75 ± 2.04 μg/mL), B.
sarmientoi (85.56 ± 3.38 μg/mL), F. galbaniflua (95.70 ±
1.82 μg/mL), M. officinalis (132.02 ± 3.14 μg/mL), M.
peruiferum (162.25 ± 1.57 μg/mL), S. sclarea (325.92 ±
8.58 μg/mL), F. officinalis (328, 28 ± 6,80 μg/mL) and P.
graveolens (363.71 ± 6.77 μg/mL). The IC50/24 h of
Amphotericin B was 0.83 ± 0.03 μg/mL (Table 1).
The cytotoxicity against L6 cells and L. amazonensis
were compared using the selectivity index (SI) (Table 1).
Higher values of SI means more promising compounds
for developing antileishmanial drugs. The SI measures
the compound’s level of selectivity towards L. amazonensis.
Evaluation of cytotoxicity showed that the least cytotoxic
EO was that of C. camphora (CC50/24 h = > 500.00 μg/
mL), followed by E. cardamomum (439.57 ± 2.27 μg/mL), L.
officinalis (377.56 ± 8.91 μg/mL), F. galbaniflua (377.26 ±
2.71 μg/mL), S. sclarea (375.37 ± 3.62 μg/mL), P. graveolens
(368.39 ± 3.90 μg/mL), F. officinalis (368.27 ± 3.81 μg/mL),
M. officinalis (297.45 ± 1.32 μg/mL), L. cubeba (180.72 ±
1.37 μg/mL), M. chamomilla (173.04 ± 1.24 μg/mL), B.
sarmientoi (163.46 ± 1.77 μg/mL), M. peruiferum (160.80 ±
1.62 μg/mL), C. odorata (142.80 ± 1.76 μg/mL), C. verbe-
naceae (130.00 ± 1.08 1.77 μg/mL), C. dinisii (106.31 ±
2.23 μg/mL) and the most cytotoxic EO was of the one
from S. guianensis (78.02 ± 1.19 μg/mL) (Table 1).
EOs with higher selectivity indexes were those from F.
galbaniflua (3.94), M. chamomilla (2.87) and M. officinalis
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(2.25), but all were more cytotoxic and less selective than
Amphotericin B, because the reference drug did not show
CC50/24 h value.
Chemical composition
The GC-MS analyses were performed for EOs that
showed the lower values of IC50 and/or the higher SI
values (Table 2). The analysis identified the main
constituents as β-farnesene (52.73 %), bisabolol oxide
(12.09 %), α-farnesene (10.34 %) for M. chamomilla;
α-copaene (13.41 %), guaiol (9.35 %), safrole (8.35 %) and
δ-cadinene (7.08 %) for M. peruiferum; linalool (28.80 %)
and linalyl acetate (60.08 %) for S. sclarea; guaiol (48.29 %)
and 2-undecanone (19.49 %) for B. sarmientoi; ethyl
phthalate (13.09 %) and methyl-8-pimaren-18-oate
(41.82 %) for F. galbaniflua; and neral (37.18 %) and
geranial (5.02 %) for M. officinalis. According to
Andrade et al. [20], EO from C. dinisii fresh leaves is
composed mainly by α-pinene (35.41 %), β-pinene
(17.81 %), sabinene (12.01 %) and bicyclogermacrene
(7.59 %). EO from S. guianensis fresh leaves contains
β-myrcene (13.14 %), germacrene-D (8.68 %) and
bicyclogermacrene (16.71 %).
Discussion
According to the classification of cytotoxicity and
antileishmanial activity for extracts and fractions derived
from plants and natural products defined by Study
Program and Disease Control [27], the evaluated
EOs are classified as moderately toxic (100 < CC50 ≤
1000 μg/mL), except the EO from S. guainensis, which
was classified as toxic (10 < CC50 ≤ 100 μg/mL).
Regarding the antileishmanial activity only EOs from S.
guianensis, C. dinisii, M. chamomilla, C. verbenaceae, B.
sarmientoi, F. galbaniflua and M. officinalis are consid-
ered moderately active (50 < IC50 ≤ 150 μg/mL). The
others are considered not active.
Considering the chemical composition of the EO from
M. chamomilla, (E)-β-farnesene and (E,E)-α-farnesene
were found as the major compound group representing
73.07 % of the total composition. These results corrobor-
ate with those reported by Machado et al. [28] that
found farnesene derivatives as the most representative
constituents (22 %) and their bioassays using EO from
Lantana camara revealed a significant leishmanicidal
activity against L. amazonensis (IC50/72 h = 0.25 μg/mL),
except for the cytotoxic activity, in which the authors
Table 1 EOs biological potential and selectivity indexes (SI) for L. amazonensis (IC50/24 h) promastigotes and L6 cells (CC50/24 h)
Essential oils L. amazonensis L6 cells SIg
IC50
a ± DP (μg/mL) CC50
f ± DP (μg/mL)
Litsea cubeba NIe 180.72 ± 1.37 -
Matricaria chamomilla 60.16 ± 4.24 173.04 ± 1.24 2.87
Elettaria cardamomum >500.00b 439.57 ± 2.27 –
Lavandula officinalis >500.00 377.56 ± 8.91 –
Cinnamomum camphora >500.00 >500.00 –
Myroxylon peruiferum 162.25 ± 1.57 160.80 ± 1.62 0.99
Salvia sclarea 325.92 ± 8.58 375.37 ± 3.62 1.15
Bulnesia sarmientoi 85.56 ± 3.38 163.46 ± 1.77 1.91
Ferula galbaniflua 95.70 ± 1.82 377.26 ± 2.71 3.94
Pelargonium graveolens 363.71 ± 6.77 368.39 ± 3.90 1.01
Cananga odorata NI 142.80 ± 1.76 –
Foeniculum officinalis 328. 28 ± 6.80 368.27 ± 3.81 1.12
Cordia verbenaceae 64.75 ± 2.04 130.00 ± 1.08 2.01
Melissa officinalis 132.02 ± 3.14 297.45 ± 1.32 2.25
Siparuna guianensis 48.55 ± 3.64 78.02 ± 1.19 1.60
Cinnamodendron dinisii 54.05 ± 4.88 106.31 ± 2.23 1.97
Anfotericina Bc (0.083 ± 0.003 μg/mL) NI –
DMSOd NI NI –
a) IC50 ± DP: the concentration able to cripple 50 % of the parasites ± standard deviation
b) > 500.00: IC50 greater than the highest concentration tested
c) Amphotericin B - positive control
d) DMSO - negative control
e) NI: no inhibition
f) CC50: the concentration able to cripple 50 % of cells after 24 h of treatment ± standard deviation
g) Selectivity index - SI = CC50 L6 / IC50 promastigotes
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Table 2 Chemical composition of selected essential oils
Content (%)
















930 932 α-pinene – – – – – – 1.83 35.41
958 963 sabinene – – – – – – – 12.01
961 970 β-pinene – – – – 17.34 – – 17.81
969 971 6-metil-5-hepten-2-one – – – – – 3.88 – –
975 0980 β-myrcene – – 1.23 – – – 13.14 1.46
1018 1024 1,8-cineole – – – 8.71 3.71 – – 4.37
1086 1092 linalool – – 28.80 2.67 – – – –
1135 1130 α-terpineol – – 5.14 – – – – –
1231 1235 neral – – – – – 37.18 – –
1247 1252 linalyl acetate – – 60.08 2.64 – – – –
1263 1264 geranial – – – – – 52.02 – –
1282 1285 safrole – 8.35 – – – – – –
1287 1293 2-undecanone – – – 19.49 – – 1.69 –
1374 1374 α-copaene – 13.41 – – – – – –
1428 1432 trans-α-bergamotene – 3.48 – – – – – –
1443 1439 (+)-aromadendrene – 2.27 – 1.26 – – – –
1451 1455 (E)-β-farnesene 52.73 – – – – – – –
1455 1458 allo-aromandrendene – 5.24 – – – – – –
1470 1474 y-gurjunene – 5.29 – – – – – –
1476 1482 germancrene-D 3.42 – – – – – 8.68 –
1478 1479 ar-curcumene – 5.05 – – – – – –
1481 1487 β-selinene – 3.27 – – – – – –
1488 1497 bicyclogermancrene – – – – – – 16.71 7.59
1504 1505 (E,E)-a-farnesene 10.34 – – – – – – –
1504 1507 β-bisabolene – 2.09 – – – – – –
1510 1511 δ-amorfene – 6.59 – – – – – –
1520 1522 δ-cadinene – 7.08 – – – – 1.04 0.14
1576 1577 (−)-spathulenol – – – 5.79 – – 4.16 1.88
1594 – diethyl phthalate – – – – 13.09 – – –
1601 1600 Guaiol – 9.35 – 48.29 – – – –
1630 – (−)-sinularene – 5.81 – – – – – –
1652 1649 β-eudesmol – 2.10 – – – – – –
1656 1656 bisabolol oxide B 12.09 – – – – – – –
1657 1658 t-cadinol – – – 1,35 – – 4.14 –
1685 1685 α-bisabolol 9.83 – – – – – 3.35 –
1732 – camazulene 2.30 – – – – – – –
– – elixene – – – – 5.87 – – –
– – methyl 8 (14)-pimaren-18- oate – – – – 41.82 – – –
– – NI – – – – 9.39 – – –
Total identified (%) 90.72 79.38 94.05 88.85 81.83 93.08 55.25 80.67
IRl literature retention rate [22], IRc retention ratio calculated by Kovats’ equation. a) Described by Andrade et al. [20]
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obtained high values on Brine shrimp (CC50 10 μg/mL).
Subsequently, Gawde et al. [29] observed that the chem-
ical composition of M. chamomilla was similar to the
one found in our study (β-farnesene, α-bisabolol oxide
B, chamazulene) but no leishmanicidal activity on L.
donavani was observed.
Studies on the chemical composition and biological
activity of M. peruiferum EO are scarce. The literature
reports (E) and (Z)-nerolidol, α-bisabolol and (E, E)-far-
nesol as its major components [30] but those com-
pounds were not identified in the present study. Santos
et al. [18] reported high levels of α-copaene in EO from
Copaifera reticulata as well as for EO from M. perui-
ferum. The last one showed growth inhibitory activity for
L. amazonensis with IC50/72 h values of 5 μg/mL for pro-
mastigotes and low cytotoxicity on J774G8 macrophages.
Ghannadi and Amree [31] have already described the
EO composition obtained from the fresh oleogum resin
and latex of Iranian F. galbaniflua (synonym F. gum-
mosa) and the main constituents of this monoterpene
rich oil were β-pinene (58.8 %). Other studies also indi-
cate β-pinene as the major compound from the fresh
oleogum resin and latex of this same specie [32, 33],
which corroborates our results. The presence of methyl
8-(14)-pimaren-18-ate, a diterpene esters hydrocarbons,
has been reported on rosin, a solid form of resin ob-
tained from pines and some other plants; and also in the
Cretaceous resins from India and Myanmar [34, 35]. To
our knowledge, there is no antileishmanial activity re-
ports related to this EO to date.
Rodilla et al. [36] determined the chemical compos-
ition of EO from B. sarmientoi. In accordance with our
work, they identified guaiol as its major component.
Studies with EO from Endlicheria bracteolata, which
has 72.12 % of guaiol in its composition, showed IC50 of
7.93 μg/mL for L. amazonensis and presented a CC50 of
15.14 μg/mL for J774.G8 macrophages [37]. The antil-
eishmanial activity may be attributed to the presence of
a hydroxyl group of alcohol characteristics in the guaiol,
especially in the exocyclic portion of the molecule [36].
The presence of linalyl acetate and linalool as the
major compounds in S. sclarea EO (total of 88.88 %)
corroborate to the results presented by Pitarokili et al.
[38] that evaluated the EO composition of S. sclarea
originated from two localities in Greece, and by Kuźma
et al. [39] that evaluated the EO composition from S.
sclarea plants generated in vitro. On the other hand,
antileishmanial activity of linalool-rich EO from leaves
of Croton cajucara against L. amazonensis was previ-
ously evaluated by Rosa et al. [40], they were able to
demonstrate morphological changes in L. amazonensis
promastigotes when treated with 15 ng/mL of that EO.
In this study the cell lysis was observed within 1 h,
indicating that the antileishmanial activity observed is
directly related to the presence of linalool, due to the ex-
istence of a hydroxyl group in the organic alcohol
function.
As in our study, the presence of the isomers of citral,
neral and geranial are constantly reported in the chem-
ical composition of the EO from M. officinalis [41–43].
Regarding the antileishmanial activity, Mikus et al. [44]
reported an IC50/72 h of 7 μg/mL for L. major, a CC50/
72 h of 25.5 μg/mL in HL-60 cells and SI of 3.6, higher
than those observed in our study. Another study has
already showed that citral presents activity against T.
cruzi, possibly by inducing cell membrane lysis with
leakage of cytoplasm [45].
The EO from C. dinisii and S. guianensis showed weak
inhibitory effect on the protozoan T. cruzi with values of
IC50/24 h = 209.30 μg/mL and 282.93 mg/mL, respect-
ively. These values are higher when compared to those
obtained in the study for L. amazonensis, 54.05 and
48.55 μg/mL, respectively [25].
The mechanism of action by which EOs inhibits para-
site growth is still not well known, but previous studies
have suggested that structural and morphological
changes are caused by drugs that inhibit ergosterol
synthesis, or interact with the membrane ergosterol
[19, 46]. Other studies indicated that the activity of
essential oils on parasites is mainly due to terpene
composition. Terpenes are responsible for the hydro-
phobic characteristic of EOs, thus allowing their diffu-
sion through the parasite cell membrane, affecting
intracellular metabolic pathways and organelles [47].
Conclusion
F. galbaniflua EO is effective against L. amazonensis
promastigotes forms and has low cytotoxic activity.
Thus, it represents a strong candidate for future studies
in order to comprehend its biological activity agaisnt L.
amazonensis.
The promising results of this study offer prospects for
further research, as the evaluation of the antileishmanial
potential of the major compounds and the elucidation of
their molecules may, in the future, contribute to the
discovery of effective drugs derived from plants for the
treatment of parasitic diseases.
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